Jaw Issues in Prostate Cancer Patients on Denosumab: Risk Factors and Prevention

What is it about?

The study aimed to evaluate the cumulative incidence of medication-related osteonecrosis of the jaw (MRONJ) in prostate cancer patients with bone metastases receiving long-term denosumab treatment. Out of 624 patients studied, MRONJ incidence was 4.6% at one year, rising to 51.9% at six years. Risk factors for MRONJ included severe disease extent, anticoagulant use, recent dental treatment, while extended denosumab dosing intervals reduced risk. Findings suggest modifying dosing schedules to mitigate MRONJ risk, emphasizing personalized treatment plans. The study highlights the need for early preventive strategies to manage this complication in patients undergoing long-term denosumab therapy.

Featured Image

Why is it important?

This research is important because it provides insights into the incidence and risk factors of medication-related osteonecrosis of the jaw (MRONJ) in patients with prostate cancer and bone metastases undergoing long-term denosumab treatment. Understanding these risk factors can lead to improved management strategies, potentially reducing the occurrence of MRONJ and enhancing the quality of life for affected patients. The study highlights the need for personalized treatment plans and preventive strategies, offering a basis for modifying denosumab dosing schedules to mitigate risks. Furthermore, it contributes to the body of knowledge regarding the side effects of bone-modifying agents in oncology, advocating for careful consideration of medication regimens in cancer patients. Key Takeaways: 1. High Incidence of MRONJ: The study demonstrates a substantial cumulative incidence of MRONJ among patients treated with denosumab, with rates reaching 51.9% after six years, underscoring the need for vigilant monitoring and management in this patient group. 2. Identified Risk Factors: Key risk factors for MRONJ include the extent of disease grade, use of anticoagulants/antiplatelets, and recent dental treatment, emphasizing the importance of assessing these factors to predict and prevent MRONJ. 3. Modifiable Risk: The research highlights that extending denosumab dosing intervals beyond one month may reduce the risk of MRONJ, suggesting a potential modification in treatment plans to minimize side effects while maintaining therapeutic efficacy.